A cancer vaccine utilizing messenger ribonucleic acid (mRNA) technology has succeeded in a phase 3 clinical trial, preventing skin cancer from recurring and spreading in patients who underwent surgery to remove the disease, pharmaceutical companies Moderna and Merck said on Aug. 19.
The Phase 3 trial represents the final stage of clinical testing required before seeking regulatory approval from the Food and Drug Administration (FDA). Both companies have not yet indicated when they plan to submit the vaccine for FDA review or how pricing might be structured if approved.
What the Left Is Saying
Democratic lawmakers and healthcare advocates have long pushed for expanded access to innovative cancer treatments, particularly those developed with taxpayer-funded research. Senator Bernie Sanders of Vermont, who has championed lower drug prices, said the success of mRNA technology in cancer treatment should be accessible to all patients regardless of income.
"If these companies received government funding for this research, then the American people have a right to affordable access," Sanders wrote on social media. The senator has previously criticized pharmaceutical companies for setting high prices on drugs developed with public investment.
Progressive healthcare groups noted that mRNA technology was validated through COVID-19 vaccines, suggesting the platform could be adapted for multiple cancer types. The Progressive Caucus Action Fund called for pricing frameworks that prioritize patient access over profit margins.
What the Right Is Saying
Republican lawmakers and free-market advocates have celebrated the announcement as a testament to American pharmaceutical innovation. Senate Minority Leader John Thune of South Dakota praised the private-sector development of breakthrough therapies, arguing that market incentives drive medical progress.
"This is exactly what happens when companies are allowed to invest in research without excessive government interference," Thune said in a statement. Representative Buddy Carter of Georgia, who serves on the House Energy and Commerce Committee, emphasized the importance of maintaining intellectual property protections to encourage continued investment.
Conservative healthcare economists have argued that price controls or government intervention could stifle the innovation pipeline. The Galen Institute noted that pharmaceutical research and development costs billions of dollars per successful drug, justifying some pricing flexibility to fund future breakthroughs.
What the Numbers Show
The FDA has approved two mRNA-based vaccines for COVID-19, both developed under emergency use authorizations that were later converted to full approval. Clinical trials for cancer treatments using mRNA technology have increased significantly since 2021, with over 40 active phase 2 or phase 3 trials currently underway in the United States according to ClinicalTrials.gov.
Pharmaceutical companies spent an estimated $139 billion on research and development globally in 2024, with oncology representing approximately 40 percent of all drug development spending, according to IQVIA data. The average cost to bring a new cancer drug from discovery to market is estimated at $2.3 billion, industry group PhRMA reported.
Medicare spending on cancer drugs reached $67 billion in 2025, representing the fastest-growing category of federal pharmaceutical expenditures, according to Medicare Payment Advisory Commission (MedPAC) reports.
The Bottom Line
The successful Phase 3 trial represents a potential significant advancement in cancer treatment using personalized mRNA technology. If approved by the FDA, the vaccine would become one of the first mRNA-based therapies for cancer prevention rather than treatment.
Both companies must still complete regulatory review processes that typically take 12 to 18 months for standard approvals. Consumer advocates will likely push for transparency around pricing and access provisions as the approval process moves forward.
The outcome could influence future policy debates around pharmaceutical pricing, government research funding, and the balance between innovation incentives and patient affordability.